Resumen

PEREZ, Virginia et al. Thioredoxin-1 Reduces Infarct Size But Does Not Improve Postischemic Ventricular Dysfunction. Rev. argent. cardiol. [online]. 2013, vol.81, n.3, pp.219-224. ISSN 1850-3748.

Background Thioredoxin-1 is a potent endogenous antioxidant involved in myocardial protection from ischemic/reperfusion injury. However, it is unknown whether this protection is preserved in middle age or whether there is dissociation between the effect on ventricular function and infarct size. Objective The purpose of this study was to compare infarct size and ventricular function in young and middle age transgenic mice overexpressing thioredoxin-1 with their corresponding wild-type controls. Methods Isolated hearts of 3-month (young) and 12-month (middle-age) FVB male mice were submitted to 30-minute global ischemia and 120 minutes reperfusion using the Langendorff technique. Four experimental groups were considered: young wild-type, middle age wild type, young thioredoxin-1 and middle age thioredoxin-1. Left ventricular function was assessed and infarct size was measured with phenyl triphenyl tetrazolium. Results Ventricular function showed no significant differences between the studied groups. However, young thioredoxin-1 mice reduced infarct size (27.6%±3.5% vs. 42.9%±6.1% in young wild-type mice); conversely, the middle age thioredoxin-1 group was not significantly different from its wild-type control (49.1%±6.4% vs. 52.6%±5.2%). Conclusions Results suggest that young mice overexpressing thioredoxin-1 reduce infarct size, but without changes in ventricular function. Moreover, the protective antioxidant effect is abolished in middle age transgenic mice.

Palabras clave : Myocardial Ischemia; Reperfusion; Myocardial Infarction; Ventricular Function; Antioxidants; Thioredoxin.

        · resumen en Español     · texto en Español     · Español ( pdf ) | Inglés ( pdf )